$ATYR
aTyr Pharma Inc

2016 Q4 Form 10-Q Financial Statement

#000156459016029228 Filed on November 14, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.380M $3.470M $3.570M
YoY Change -11.29% -2.8% 96.15%
% of Gross Profit
Research & Development $9.140M $10.40M $7.739M
YoY Change -27.86% 34.32% 75.49%
% of Gross Profit
Depreciation & Amortization $220.0K $220.0K $220.0K
YoY Change -4.35% 0.0% 4.76%
% of Gross Profit
Operating Expenses $12.53M $13.87M $11.31M
YoY Change -24.0% 22.56% 81.56%
Operating Profit -$13.87M -$11.31M
YoY Change 22.56% 81.56%
Interest Expense -$60.00K
YoY Change 50.0%
% of Operating Profit
Other Income/Expense, Net $46.00K -$16.00K
YoY Change -387.5% -96.0%
Pretax Income -$12.62M -$13.82M -$11.33M
YoY Change -23.47% 21.98% 70.89%
Income Tax -$50.00K
% Of Pretax Income
Net Earnings -$12.57M -$13.82M -$11.33M
YoY Change -23.81% 21.98% 70.85%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$7.438M -$8.178M -$6.704M
COMMON SHARES
Basic Shares Outstanding 23.72M 23.64M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $72.15M $70.53M $108.8M
YoY Change -24.48% -35.17% 362.98%
Cash & Equivalents $38.39M $34.33M $60.05M
Short-Term Investments $33.76M $36.20M $48.80M
Other Short-Term Assets $2.600M $3.100M $2.600M
YoY Change 8.33% 19.23% 333.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $74.80M $73.60M $111.4M
YoY Change -23.63% -33.92% 364.09%
LONG-TERM ASSETS
Property, Plant & Equipment $1.421M $1.596M $1.841M
YoY Change -20.75% -13.31% -12.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $4.000M $10.30M $28.00M
YoY Change -86.58% -63.21%
Other Assets $333.0K $353.0K $137.0K
YoY Change 182.2% 157.66% -77.17%
Total Long-Term Assets $5.724M $12.33M $29.99M
YoY Change -81.96% -58.9% 971.0%
TOTAL ASSETS
Total Short-Term Assets $74.80M $73.60M $111.4M
Total Long-Term Assets $5.724M $12.33M $29.99M
Total Assets $80.52M $85.93M $141.4M
YoY Change -37.9% -39.22% 427.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.606M $3.565M $1.590M
YoY Change -32.7% 124.21% 32.5%
Accrued Expenses $5.450M $5.500M $3.569M
YoY Change 18.61% 54.1% 11.53%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $339.0K $2.600M $3.300M
YoY Change -89.93% -21.21% -35.29%
Total Short-Term Liabilities $8.525M $11.90M $8.776M
YoY Change -29.82% 35.6% -15.62%
LONG-TERM LIABILITIES
Long-Term Debt $9.198M $0.00 $2.600M
YoY Change 417.91% -100.0% -55.93%
Other Long-Term Liabilities $0.00 $0.00 $585.0K
YoY Change -100.0% -100.0% -26.88%
Total Long-Term Liabilities $9.198M $0.00 $585.0K
YoY Change 291.9% -100.0% -91.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.525M $11.90M $8.776M
Total Long-Term Liabilities $9.198M $0.00 $585.0K
Total Liabilities $17.72M $11.90M $9.361M
YoY Change 22.27% 27.12% -52.24%
SHAREHOLDERS EQUITY
Retained Earnings -$216.0M -$141.6M
YoY Change 36.59%
Common Stock $278.9M $270.9M
YoY Change 2.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $62.80M $74.00M $129.2M
YoY Change
Total Liabilities & Shareholders Equity $80.52M $85.90M $141.4M
YoY Change -37.9% -39.24% 427.5%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$12.57M -$13.82M -$11.33M
YoY Change -23.81% 21.98% 70.85%
Depreciation, Depletion And Amortization $220.0K $220.0K $220.0K
YoY Change -4.35% 0.0% 4.76%
Cash From Operating Activities -$11.69M -$14.69M -$9.460M
YoY Change 18.8% 55.29% 63.95%
INVESTING ACTIVITIES
Capital Expenditures -$50.00K -$60.00K -$390.0K
YoY Change -54.55% -84.62%
Acquisitions
YoY Change
Other Investing Activities $8.650M $6.750M $7.620M
YoY Change 115.17% -11.42% 1072.31%
Cash From Investing Activities $8.600M $6.690M $7.240M
YoY Change 119.95% -7.6% 1013.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.150M -860.0K -790.0K
YoY Change -755.96% 8.86% 2.6%
NET CHANGE
Cash From Operating Activities -11.69M -14.69M -9.460M
Cash From Investing Activities 8.600M 6.690M 7.240M
Cash From Financing Activities 7.150M -860.0K -790.0K
Net Change In Cash 4.060M -8.860M -3.010M
YoY Change -157.83% 194.35% -48.9%
FREE CASH FLOW
Cash From Operating Activities -$11.69M -$14.69M -$9.460M
Capital Expenditures -$50.00K -$60.00K -$390.0K
Free Cash Flow -$11.64M -$14.63M -$9.070M
YoY Change 19.63% 61.3% 57.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Trading Symbol
TradingSymbol
LIFE
dei Entity Registrant Name
EntityRegistrantName
ATYR PHARMA INC
dei Entity Central Index Key
EntityCentralIndexKey
0001339970
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23718529
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53025000
CY2015Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
42510000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2415000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
97950000
CY2015Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
29814000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
118000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3872000
CY2015Q4 life Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
4595000
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
315000
CY2015Q4 us-gaap Loans Payable Current
LoansPayableCurrent
3366000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
571000
CY2015Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23718529
CY2016Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
7000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1793000
CY2015Q4 us-gaap Long Term Loans From Bank
LongTermLoansFromBank
1776000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21834000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3470000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Assets
Assets
129675000
CY2016Q3 us-gaap Assets
Assets
85925000
CY2016Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
353000
CY2016Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3565000
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23718529
CY2016Q3 life Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
5520000
CY2016Q3 us-gaap Loans Payable Current
LoansPayableCurrent
2640000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3574000
CY2016Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
10329000
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1596000
CY2016Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
211000
CY2016Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11711000
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10395000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7739000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33702000
CY2016Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
36198000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31548000
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
38000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
178000
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23581001
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13221551
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11291000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.38
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-68000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2625280
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45111000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
11313000
us-gaap Operating Expenses
OperatingExpenses
45413000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
13865000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
46000
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-16000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
124000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-13819000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-11329000
us-gaap Net Income Loss
NetIncomeLoss
-45289000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
15000
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13819000
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11329000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.91
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23696511
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23669154
CY2016Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-12000
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13831000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
679000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
643000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1411000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3877000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2469000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
130000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
238000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-29000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-496000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-479000
life Increase Decrease In Deferred Rent Credit
IncreaseDecreaseInDeferredRentCredit
-234000
life Increase Decrease In Deferred Rent Credit
IncreaseDecreaseInDeferredRentCredit
-219000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
937000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1192000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
112000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
718000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-41166000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-26962000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
554000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
545000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
26244000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
99408000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
51723000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
24055000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
24925000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-75898000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
75648000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
77246000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
533000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
75000
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
2547000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2000000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
149014000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
46154000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13899000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23670079
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23670079
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9299000
us-gaap Operating Expenses
OperatingExpenses
31133000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13865000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11313000
us-gaap Operating Income Loss
OperatingIncomeLoss
-45413000
us-gaap Operating Income Loss
OperatingIncomeLoss
-31133000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-347000
us-gaap Net Income Loss
NetIncomeLoss
-31480000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4420664
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-45289000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-31495000
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
2413000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-2452000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-18693000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60053000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Our consolidated financial statements are prepared in accordance with GAAP. The preparation of our consolidated financial statements requires us to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements and accompanying notes. The most significant estimates in our consolidated financial statements relate to the fair value of equity issuances and awards, and clinical trials and research and development expense accruals. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions.</p></div>
life Registration Statement Filing Date
RegistrationStatementFilingDate
2016-06-13
CY2016Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
21871
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4420664
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
15892
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
623469
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4248838
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.83
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.56
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.24
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
10.79
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.83
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1509249
CY2016Q3 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
7
life Available For Sale Securities In Gross Unrealized Loss Position Maturities Term Maximum
AvailableForSaleSecuritiesInGrossUnrealizedLossPositionMaturitiesTermMaximum
P12M
life Noncancelable Operating Leases Term Of Expiration
NoncancelableOperatingLeasesTermOfExpiration
2017-05
CY2011Q4 life Lease Agreement Extended Term
LeaseAgreementExtendedTerm
P5Y
CY2016Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2015Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
CY2015Q2 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2000000
CY2015Q2 us-gaap Interest Paid
InterestPaid
500000
CY2016Q2 life Sublease Agreement Commenced Date
SubleaseAgreementCommencedDate
2016-08
CY2016Q2 life Sublease Agreement Expiration Date
SubleaseAgreementExpirationDate
2017-06
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
232000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
386000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
618000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2262919
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1224000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1050000
CY2016Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6046633
CY2015Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4766580

Files In Submission

Name View Source Status
0001564590-16-029228-index-headers.html Edgar Link pending
0001564590-16-029228-index.html Edgar Link pending
0001564590-16-029228.txt Edgar Link pending
0001564590-16-029228-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
life-10q_20160930.htm Edgar Link pending
life-20160930.xml Edgar Link completed
life-20160930.xsd Edgar Link pending
life-20160930_cal.xml Edgar Link unprocessable
life-20160930_def.xml Edgar Link unprocessable
life-20160930_lab.xml Edgar Link unprocessable
life-20160930_pre.xml Edgar Link unprocessable
life-ex101_362.htm Edgar Link pending
life-ex311_7.htm Edgar Link pending
life-ex312_8.htm Edgar Link pending
life-ex321_6.htm Edgar Link pending
life-ex322_9.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending